Skip to main content

Lexeo Therapeutics, Inc.

LXEO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001907108

In the last 90 days, Lexeo Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 152 institutions reported holding it in 13F filings for Q3 2026, worth $310.0M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 19, 2026
$244.2M
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $18.2K in total
3
13F holdersQ3 2026, +15 vs. previous quarter
152
13F valueReported value at the end of Q3 2026
$310.0M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$100.0M
No comparable prior period
Free cash flow, FY2025
-$99.0M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
17.0M
Shares sold short
Change
−516.1K
−2.9% vs. previous
Days to cover
12.73
At average daily volume

Superinvestors holding LXEO, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding LXEO at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Lexeo Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 18, 2026 (view filing)5:00 PM ETNov 171 dayTamayo Louis EdwardChief Financial OfficerSSale−1.01K$3.26−$3.28K−1.1%91.9K after
Nov 18, 2026 (view filing)5:00 PM ETNov 171 dayOtero Jose ManuelChief Operating OfficerSSale−1.28K$3.26−$4.19K−0.9%137.0K after
Nov 18, 2026 (view filing)5:00 PM ETNov 171 dayTownsend Richard NolanChief Executive OfficerSSale−3.29K$3.26−$10.7K−0.9%373.5K after
Aug 19, 2026 (view filing)5:00 PM ETAug 181 dayTamayo Louis EdwardChief Financial OfficerSSale−4.12K$4.91−$20.2K−4.2%92.9K after
Aug 19, 2026 (view filing)5:00 PM ETAug 181 dayTownsend Richard NolanChief Executive OfficerSSale−3.35K$4.95−$16.6K−0.9%374.5K after
Aug 19, 2026 (view filing)5:00 PM ETAug 181 dayOtero Jose ManuelChief Operating OfficerSSale−1.30K$4.96−$6.46K−0.9%136.2K after
Jul 1, 2026 (view filing)6:49 PM ETJul 1Same dayTamayo Louis EdwardChief Financial OfficerSSale−4.64K$4.49−$20.8K−4.6%97.0K after
Jul 1, 2026 (view filing)6:49 PM ETJul 1Same dayOtero Jose ManuelChief Operating OfficerSSale−4.67K$4.48−$20.9K−3.3%137.5K after
Jul 1, 2026 (view filing)6:48 PM ETJul 1Same dayBhalla Narinder PalChief Medical OfficerSSale−22.3K$4.42−$98.6K−21.3%82.2K after
Jul 1, 2026 (view filing)6:47 PM ETJul 1Same dayTownsend Richard NolanChief Executive OfficerSSale−25.9K$4.48−$116.2K−6.4%377.8K after

Top 10 13F holders, Q3 2026

See all 152 holders

The largest institutional positions in Lexeo Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding LXEO in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Affinity Asset Advisors, LLC7,245,611$24.5M1.39%+1,438,000+24.8%Added
Suvretta Capital Management, LLC6,384,200$21.6M0.60%00.0%Unchanged
BlackRock, Inc.5,973,615$20.2M0.00%+234,160+4.1%Added
Ra Capital Management, L.P.5,000,000$16.9M0.17%00.0%Unchanged
Frazier Life Sciences Management, L.P.4,824,725$16.3M0.40%00.0%Unchanged
JPMorgan Chase & Co4,583,248$15.7M0.00%+4,486,958+4,659.8%Added
Vestal Point Capital, LP4,320,000$14.6M0.38%00.0%Unchanged
Citadel Advisors LLC4,236,938$14.3M0.01%+338,368+8.7%Added
Balyasny Asset Management LLC3,987,787$13.5M0.03%+1,575,045+65.3%Added
Millennium Management LLC3,778,541$12.8M0.01%+944,919+33.3%Added

Holders of 5% or more of LXEO

See all 11 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lexeo Therapeutics, Inc..

Largest holders of LXEO from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Balyasny Asset Management LLC13G/A9.99%8.20M shares0.00 ppfrom 9.99%Aug 14, 20256 filingsNov 16, 2026SEC
Affinity Asset Advisors, LLC13G/A9.80%8.11M shares+1.40 ppfrom 8.40%Jun 4, 20254 filingsNov 13, 2026SEC
Suvretta Capital Management, LLC13G7.70%5.67M sharesNewApr 13, 20261 filingApr 13, 2026SEC
Citadel Advisors LLC13G/A7.40%5.50M shares−2.20 ppfrom 9.60%Nov 17, 20234 filingsFeb 17, 2026SEC
Janus Henderson Group PLC13G/A7.20%5.94M shares−2.79 ppfrom 9.99%Feb 14, 20249 filingsNov 16, 2026SEC